Clinical trials: Iris
Pancreatic Cancer
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic…
- Trial name
- NCT02551991
- Testing
- nal-IRI, 5 fluorouracil, Leucovorin
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Ipsen
Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
- Trial name
- IRIS (NCT00761007)
- Testing
- Ibodutant
- Where
- 6 sites in Denmark, Germany and 4 more
- Volunteers
- 554 people
- Sponsor
- Menarini Group
Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome
Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery
The purpose of this study is to evaluate the effect of OMS302 on the signs of Intraoperative Floppy Iris Syndrome in patients at risk.
- Trial name
- NCT02093689
- Testing
- Part 1 OMS302, Part 2 OMS302
- Where
- 2 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Retinitis Pigmentosa, Cone Rod Dystrophy
Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V1)
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Trial name
- IRIS-1 (NCT01864486)
- Testing
- Intelligent Retinal Implant System
- Where
- 5 sites in Austria, France and 1 more
- Volunteers
- 20 people
- Sponsor
- Science Corporation
Retinitis Pigmentosa, Cone-Rod Dystrophy
IRIS PILOT - Extended Pilot Study With a Retinal Implant System
Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.
- Conditions
- Retinitis Pigmentosa, Cone-Rod Dystrophy, Choroideremia
- Trial name
- NCT00427180
- Testing
- Retinal Implant System (IRIS)
- Volunteers
- 20 people
- Sponsor
- Intelligent Medical Implants GmbH
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Influenza
Influenza Resistance Information Study
This study will assist in the early detection of influenza resistant to antivirals and will monitor the clinical outcome of adults and children infected with influenza according to subtype and susceptibility.
- Trial name
- IRIS (NCT00884117)
- Testing
- Oseltamivir
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 4,561 people
- Sponsor
- Hoffmann-La Roche
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084656
- Testing
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Enteral Nutrition, Feeding Tube Placement
Case Series to Evaluate the Identification of Anatomical Markers Using the KANGAROO™ Feeding Tube
This is a prospective, single-center, open label, within-subject clinical trial to evaluate the identification of anatomical markers in the gastrointestinal tract using the IRIS feeding tube.
- Trial name
- NCT02430571
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Medtronic - MITG
Mitral Valve Insufficiency
Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System
Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.
- Trial name
- NCT02607527
- Testing
- Mitral Valve IRIS Ring
- Where
- 2 sites in Brazil, Paraguay
- Volunteers
- 21 people
- Sponsor
- Boston Scientific Corporation
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Cataract, Astigmatism
Astigmatism Correction With Intrastromal Arcuate Incisions in Eyes Undergoing Cataract Surgery With Femtosecond Laser Using the Cassini Ambient With Iris Registration (ARCUATAS)
This is an observational, prospective follow-up post-marketing study of CE marked medical devices aimed at treating astigmatism in patients with cataracts.
- Trial name
- ARCUATAS (NCT05053620)
- Testing
- Calculation of the arcuate intrasomal incisions
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- OFTALVIST (Oftalmología Vistahermosa S.L)
Ischemia-Reperfusion Injury
Remote Ischemic Conditioning Using the autoRIC
The purpose of the study is to evaluate the hypothesis that patients receiving remote ischemic conditioning using the autoRIC device show statistically significant reduction in the prevalence of ischemia-reperfusion injury to the…
- Trial name
- SHIELD (NCT03318575)
- Testing
- autoRIC
- Where
- 16 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- CellAegis US, Inc.
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Myocardial Infarction
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack.
- Trial name
- IRI-EXPLORE (NCT06139328)
- Testing
- BI 765845
- Where
- 53 sites in Australia, Canada and 12 more
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Glaucoma, Glaucoma, Open Angle
AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
- Trial name
- NCT02036541
- Testing
- AqueSys XEN 45 Glaucoma Implant
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- AqueSys, Inc.
Aniridia
Study of Ataluren in Participants With Nonsense Mutation Aniridia
This study is designed to evaluate the effect of ataluren on Maximum Reading Speed as measured using the Minnesota Low Vision Reading Test (MNREAD) Acuity Charts in participants with nonsense mutation aniridia.
- Trial name
- STAR (NCT02647359)
- Testing
- Ataluren
- Where
- 3 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- PTC Therapeutics
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Age-related Macular Degeneration (AMD)
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
This was a retrospective cohort study to assess the treatment history, demographic characteristics, clinical characteristics, and early treatment patterns of patients who received brolucizumab for neovascular age-related macular…
- Trial name
- NCT05037396
- Testing
- Brolucizumab
- Where
- United States
- Volunteers
- 9,457 people
- Sponsor
- Novartis Pharmaceuticals
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals